Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for LeonaBio, Inc. (LONA : NSDQ)
 
 • Company Description   
LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington.

Number of Employees: 19

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.35 Daily Weekly Monthly
20 Day Moving Average: 93,545 shares
Shares Outstanding: 3.94 (millions)
Market Capitalization: $44.76 (millions)
Beta: 2.22
52 Week High: $14.21
52 Week Low: $2.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 114.15% 119.27%
12 Week 68.15% 77.95%
Year To Date 49.93% 55.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18706 North Creek Parkway Suite 104
-
Bothell,WA 98011
USA
ph: 425-620-8501
fax: -
ir@leonabio.com https://leonabio.com
 
 • General Corporate Information   
Officers
Mark Litton - President; Chief Executive Officer and Director
Kelly A. Romano - Chairwoman of the Board of Directors
Robert Renninger - Chief Financial Officer
Joseph Edelman - Director
James A. Johnson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04746L203
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 05/08/26
Share - Related Items
Shares Outstanding: 3.94
Most Recent Split Date: 9.00 (0.10:1)
Beta: 2.22
Market Capitalization: $44.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.89 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/08/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.61
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 77.60%
vs. Previous Quarter: 6.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -
12/31/25 - -340.97
09/30/25 - -107.06
ROA
03/31/26 - -
12/31/25 - -209.91
09/30/25 - -89.89
Current Ratio
03/31/26 - -
12/31/25 - 1.88
09/30/25 - 9.70
Quick Ratio
03/31/26 - -
12/31/25 - 1.88
09/30/25 - 9.70
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Book Value
03/31/26 - -
12/31/25 - 7.05
09/30/25 - 6.79
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - -
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - -
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©